Remibrutinib

• A Phase 3 extension study to assess the long-term safety and efficacy of remibrutinib in adult participants with moderate to severe hidraden… Pending
  2025-523259-72-00 Phase III 12 countries Novartis Pharma AG
• A clinical trial to provide continued access to remibrutinib (LOU064) for people who are benefiting from it in a previous remibrutinib trial Pending
  2025-524078-40-00 Phase III 6 countries Novartis Pharma AG
• A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosi… Recruiting
  2025-521546-23-00 Phase III 23 countries Novartis Pharma AG
• Efficacy and safety of remibrutinib after switching from ocrelizumab in participants living with relapsing multiple sclerosis, followed by o… Recruiting
  2023-509275-17-00 Phase III 10 countries Novartis Pharma AG
• A 12-week randomized, participant and investigator blinded, placebo-controlled, exploratory study in adult participants with Chronic Urticar… Recruiting
  2024-516355-41-00 Phase II 4 countries Novartis Pharma AG
• A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of remibrutinib in patient… Recruiting
  2023-510026-32-00 Phase III 8 countries Novartis Pharma AG
• 24 weeks double-blind randomized placebo-controlled trial to evaluate efficacy, PK, safety of LOU064 in adolescents (12 - <18) with CSU and … Recruiting
  2022-502159-78-00 Phase III 5 countries Novartis Pharma AG
• A Phase 3 study to assess efficacy, safety and tolerability of remibrutinib in adult and adolescent patients with moderate to severe hidrade… Ended
  2024-513266-19-00 Phase III 10 countries Novartis Pharma AG
• A Phase 3 study to assess efficacy, safety and tolerability of remibrutinib in adult and adolescent patients with moderate to severe hidrade… Ended
  2024-513282-39-00 Phase III 9 countries Novartis Pharma AG
• A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy,… Ended
  2023-505739-12-01 Phase III 10 countries Novartis Pharma AG
• 52 weeks double-blind, double-dummy, randomized placebo-controlled trial to evaluate safety, efficacy and tolerability of remibrutinib in co… Ended
  2022-502161-19-00 Phase III 10 countries Novartis Pharma AG
• An extension study of long-term efficacy, safety and tolerability of remibrutinib in chronic spontaneous urticaria patients who completed pr… Ended
  2024-510818-33-00 Phase III 10 countries Novartis Pharma AG
• Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treat… Ended
  2023-509345-12-00 Phase III 13 countries Novartis Pharma AG
• Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treat… Ended
  2023-509372-41-00 Phase III 15 countries Novartis Pharma AG

Showing 1–14 of 14 trials